AVM Receives FDA Permission for Clinical Trials in COVID-19/ARDS

Seattle, September 16,2020 – AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients.